OBJECTIVE: The aim of this study was to determine the genomic alterations of cancer-related genes in advanced medullary thyroid carcinoma during the course of clinical care. METHODS: Hybrid-capture-based comprehensive genomic profiling was performed on 34 consecutive medullary thyroid carcinoma cases to identify all four classes of genomic alterations, and outcome for an index patient was collected. RESULTS: RET was mutated in 88% (30/34) of cases, with RET M918T being responsible for 70% (21/30) of the RET alterations. The other RET alterations were RET E632_L633del, C634R, C620R, C618G/R/S, V804M, and RET amplification. Two of the four RET wild-type patients harbored mutations in KRAS or HRAS (1/34 each). The next most frequent genomic alterations were amplifications of CCND1, FGF3, and FGF19 and alterations in CDKN2A (3/34 each). One case with a RET M918T mutation developed acquired resistance to progressively dose-escalated vandetanib. When the mTOR inhibitor everolimus was added to continued vandetanib treatment, the patient achieved a second 25% reduction of tumor volume (RECIST 1.1) for 8 months. CONCLUSIONS: Comprehensive genomic profiling identified the full breadth of RET alterations in metastatic medullary thyroid carcinoma and possible cooperating oncogenic driver alterations. This approach may refine the use of targeted therapy for these patients.
OBJECTIVE: The aim of this study was to determine the genomic alterations of cancer-related genes in advanced medullary thyroid carcinoma during the course of clinical care. METHODS: Hybrid-capture-based comprehensive genomic profiling was performed on 34 consecutive medullary thyroid carcinoma cases to identify all four classes of genomic alterations, and outcome for an index patient was collected. RESULTS: RET was mutated in 88% (30/34) of cases, with RET M918T being responsible for 70% (21/30) of the RET alterations. The other RET alterations were RET E632_L633del, C634R, C620R, C618G/R/S, V804M, and RET amplification. Two of the four RET wild-type patients harbored mutations in KRAS or HRAS (1/34 each). The next most frequent genomic alterations were amplifications of CCND1, FGF3, and FGF19 and alterations in CDKN2A (3/34 each). One case with a RET M918T mutation developed acquired resistance to progressively dose-escalated vandetanib. When the mTOR inhibitor everolimus was added to continued vandetanib treatment, the patient achieved a second 25% reduction of tumor volume (RECIST 1.1) for 8 months. CONCLUSIONS: Comprehensive genomic profiling identified the full breadth of RET alterations in metastatic medullary thyroid carcinoma and possible cooperating oncogenic driver alterations. This approach may refine the use of targeted therapy for these patients.
Authors: L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi Journal: Nature Date: 1993-06-03 Impact factor: 49.962
Authors: Wendy van Veelen; Rob Klompmaker; Martijn Gloerich; Carola J R van Gasteren; Eric Kalkhoven; Ruud Berger; Cornelis J M Lips; Rene H Medema; Jo W M Höppener; Dennis S Acton Journal: Int J Cancer Date: 2009-01-15 Impact factor: 7.396
Authors: Nishant Agrawal; Yuchen Jiao; Mark Sausen; Rebecca Leary; Chetan Bettegowda; Nicholas J Roberts; Sheetal Bhan; Allen S Ho; Zubair Khan; Justin Bishop; William H Westra; Laura D Wood; Ralph H Hruban; Ralph P Tufano; Bruce Robinson; Henning Dralle; Sergio P A Toledo; Rodrigo A Toledo; Luc G T Morris; Ronald A Ghossein; James A Fagin; Timothy A Chan; Victor E Velculescu; Bert Vogelstein; Kenneth W Kinzler; Nickolas Papadopoulos; Barry D Nelkin; Douglas W Ball Journal: J Clin Endocrinol Metab Date: 2012-12-21 Impact factor: 5.958
Authors: A Faggiano; V Ramundo; A Dicitore; S Castiglioni; M O Borghi; R Severino; P Ferolla; L Crinò; A Abbruzzese; P Sperlongano; M Caraglia; D Ferone; L Hofland; A Colao; G Vitale Journal: J Cell Mol Med Date: 2012-07 Impact factor: 5.310
Authors: James Saller; Shabnam Seydafkan; Mohammad Shahid; Manoj Gadara; Mauro Cives; Steven A Eschrich; David Boulware; Jonathan R Strosberg; Nasir Aejaz; Domenico Coppola Journal: Cancer Genomics Proteomics Date: 2019 Sep-Oct Impact factor: 4.069
Authors: Pierre Vanden Borre; Alexa B Schrock; Peter M Anderson; John C Morris; Andreas M Heilmann; Oliver Holmes; Kai Wang; Adrienne Johnson; Steven G Waguespack; Sai-Hong Ignatius Ou; Saad Khan; Kar-Ming Fung; Philip J Stephens; Rachel L Erlich; Vincent A Miller; Jeffrey S Ross; Siraj M Ali Journal: Oncologist Date: 2017-02-16
Authors: Jacob J Adashek; Aakash P Desai; Alexander Y Andreev-Drakhlin; Jason Roszik; Gilbert J Cote; Vivek Subbiah Journal: Mol Cancer Ther Date: 2021-09-06 Impact factor: 6.261
Authors: Elizabeth G Grubbs; Michelle D Williams; Paul Scheet; Selina Vattathil; Nancy D Perrier; Jeffrey E Lee; Robert F Gagel; Tao Hai; Lei Feng; Maria E Cabanillas; Gilbert J Cote Journal: Thyroid Date: 2016-10-18 Impact factor: 6.568
Authors: Ira L Kraft; Srivandana Akshintala; John W Glod; Jack F Shern; Brigitte C Widemann; Yuelin Zhu; Haiyan Lei; Claudia Derse-Anthony; Eva Dombi; Seth M Steinberg; Maya Lodish; Steven G Waguespack; Oxana Kapustina; Elizabeth Fox; Frank M Balis; Maria J Merino; Paul S Meltzer Journal: Clin Cancer Res Date: 2017-11-29 Impact factor: 12.531